Wield Therapeutics
Wield Therapeutics develops treatments for autoimmune diseases by targeting the root causes of inflammation to induce durable, drug-free remissions. The company uses human genetic validation and multi-omic data networks to identify disease-driving targets and stratify patients by molecular pathway, increasing clinical trial success probability by 2-3x.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Autoimmune diseases are highly heterogeneous, meaning that effective drugs can be missed when patients are not diagnosed according to the specific molecular pathways driving their disease. This heterogeneity complicates clinical trials and treatment development, often leading to failed trials and delayed access to effective therapies for patients who need them.
Solution
Wield Therapeutics develops treatments for autoimmune diseases by addressing the root causes of inflammation to induce durable, drug-free remissions. The company connects networks of associations in genetic and multi-omic data to identify targets involved in autoimmune disease, with programs rooted in strong human genetic validation. Their approach identifies patients most likely to respond to their therapeutics based on molecular pathways, allowing for smaller, faster, and more efficient clinical trials. By tailoring statistical analyses to evaluate rapid efficacy, the company increases the probability of clinical success by 2-3x compared to standard approaches.
Target Audience
Primary customers are autoimmune disease patients who have not achieved remission through existing treatments, as well as clinical partners and investigators seeking more efficient, genetically informed therapeutic development.
Features
- Human genetic validation underpinning therapeutic targets, increasing probability of clinical success by 2-3x
- Integration of genetic and multi-omic data networks to identify disease-driving targets
- Molecular patient stratification to match patients with the pathways driving their specific disease
- Trial design optimized for smaller cohorts with statistical analyses geared toward detecting rapid efficacy
- Focus on inducing durable, drug-free remissions rather than chronic symptom management